TNF and rheumatoid arthritis: It is noteworthy to mention that periodontitis is associated with an increased risk of etanercept discontinuation with an hazard ratio of 1.27 (95% CI, 1.01–1.60) in anti-TNF-naïve rheumatoid arthritis patients if they have been diagnosed with periodontitis within 5 years prior to or during etanercept treatment [194].